Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-1119 PK and Food Effect in Healthy Chinese Adults
NCT03776968Phase 1Completed
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deutenzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hinova Pharmaceuticals Inc. Primary endpoints: Area under the plasma concentration-time curve from time 0 to infinity at Day 50, Area under the plasma concentration-time curve from time 0 to last measurable concentration at Day 50 and 6 more. Started Oct 2017; status: completed.
02
Drugs
deutenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03776968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776968.